Valuation: Omeros Corporation

Market Cap 1.29B 1.13B 1.07B 967M 1.81B 124B 1.82B 12.76B 4.92B 63.11B 4.86B 4.75B 203B P/E 2026 *
20.1x
P/E 2027 * 17.9x
Enterprise Value 1.29B 1.13B 1.07B 967M 1.81B 124B 1.82B 12.76B 4.92B 63.11B 4.86B 4.75B 203B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 6.54x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-3.14%
1 week-2.24%
Current month-4.90%
1 month+3.96%
3 months+73.83%
6 months+63.20%
Current year+4.05%
1 week 16.5
Extreme 16.5001
18.69
1 month 16.5
Extreme 16.5001
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 4.06
Extreme 4.055
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Exercice

General Counsel

75,000 0.1036%
8/27/26 Exercice

Director

30,000 0.0415%
8/24/26 Exercice

Chief Financial Officer

2,718 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-3.14%-2.24%+319.48%+489.77% 1.29B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.85%+1.26%+65.44%+237.01% 27.61B
Weighted average by Cap. -0.48%+1.42%+37.83%+149.58%

Financials

2026 *2027 *
Net sales 126M 110M 103M 93.91M 176M 12.05B 177M 1.24B 478M 6.13B 472M 461M 19.72B 198M 172M 163M 148M 277M 18.98B 278M 1.95B 753M 9.65B 743M 727M 31.05B
Net income 63.3M 55.2M 52.12M 47.33M 88.67M 6.07B 89.04M 624M 241M 3.09B 238M 233M 9.94B 79.47M 69.29M 65.43M 59.42M 111M 7.63B 112M 784M 302M 3.88B 299M 292M 12.47B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-09-18 $17.87 -3.14% 2,151,925
26-09-17 $18.45 +6.40% 2,567,943
26-09-16 $17.34 +0.99% 2,108,105
26-09-15 $17.17 -1.66% 1,655,628
26-09-14 $17.46 -4.49% 1,691,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.87USD
Average target price
33.00USD
Spread / Average Target
+84.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!